Tudor Investment Corp ET AL Invests $748,000 in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Tudor Investment Corp ET AL purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 99,450 shares of the biotechnology company's stock, valued at approximately $748,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Venturi Wealth Management LLC purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter worth $46,000. R Squared Ltd purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter worth $48,000. KBC Group NV increased its position in BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock worth $77,000 after buying an additional 4,537 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter worth $80,000. Finally, Syon Capital LLC purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter worth $99,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BCRX has been the subject of several recent research reports. Wedbush initiated coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target for the company. StockNews.com upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, May 6th. Evercore ISI lifted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research report on Monday, January 13th. Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price target for the company. Finally, Needham & Company LLC lifted their price target on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $16.56.

BioCryst Pharmaceuticals Stock Up 4.6%

NASDAQ:BCRX traded up $0.46 during trading hours on Monday, hitting $10.43. 3,490,168 shares of the company's stock traded hands, compared to its average volume of 3,912,376. The firm has a market cap of $2.18 billion, a P/E ratio of -17.09 and a beta of 1.08. BioCryst Pharmaceuticals, Inc. has a 52 week low of $5.34 and a 52 week high of $11.11. The business's fifty day simple moving average is $7.87 and its two-hundred day simple moving average is $7.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. The business's revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period last year, the company earned $0.28 earnings per share. On average, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.